Symbols / MANE Stock $67.84 -2.04% Veradermics, Incorporated
MANE (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.
Ratings
Current target
$67.84
Low
$85.00
High
$111.00
Mean
$95.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-22 | main | Leerink Partners | Outperform → Outperform | $90 |
| 2026-03-02 | init | Cantor Fitzgerald | — → Overweight | — |
| 2026-03-02 | init | Citigroup | — → Buy | $85 |
| 2026-03-02 | init | Leerink Partners | — → Outperform | $75 |
| 2026-03-02 | init | Jefferies | — → Buy | $75 |
- MANE Stock Price and Chart — NYSE:MANE - TradingView Sun, 12 Apr 2026 07
- Is MANE Stock Worth Watching Right Now - Kalkine Media Sat, 25 Apr 2026 05
- symbol__ Stock Quote Price and Forecast - CNN hu, 29 Jan 2026 04
- Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal? - Yahoo Finance Wed, 11 Mar 2026 07
- MANE (MANE) Stock Forecast and Price Target 2026 - MarketBeat Mon, 16 Feb 2026 00
- MANE Maintained by Leerink Partners -- Price Target Raised to $9 - GuruFocus Wed, 22 Apr 2026 16
- Insider Stock Purchases: February 06, 2026 | MANE Stock News - Quiver Quantitative Fri, 06 Feb 2026 08
- Is Veradermics (MANE) Pricing Fully Reflect Its 96% Year To Date Surge - simplywall.st Fri, 17 Apr 2026 07
- Veradermics stock surges on public debut (MANE:NYSE) - Seeking Alpha Wed, 04 Feb 2026 08
- Biotech Targeting Hair Loss Doubles in Stock IPO. It Has No Revenue. - Barron's Wed, 04 Feb 2026 08
- A cut above: Veradermics locks in $256M IPO and shares spike - Fierce Pharma hu, 05 Feb 2026 08
- Is Veradermics (MANE) Pricing Fully Reflect Its 96% Year To Date Surge - Sahm Sat, 18 Apr 2026 08
- Dermatology drug maker Veradermics set for Miami investor spotlight - Stock Titan ue, 03 Mar 2026 08
- Assessing Veradermics (MANE) Valuation After Strong Year To Date Gains And Recent Pullback - Yahoo Finance hu, 23 Apr 2026 17
- MANE (NYSE:MANE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat Fri, 24 Apr 2026 09
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
71.56
+171.21%
|
26.38
+52.30%
|
17.32
|
| Research And Development |
|
62.06
+166.57%
|
23.28
+55.52%
|
14.97
|
| Selling General And Administration |
|
10.28
+194.19%
|
3.50
+48.53%
|
2.35
|
| General And Administrative Expense |
|
10.28
+194.19%
|
3.50
+48.53%
|
2.35
|
| Other Gand A |
|
10.28
+194.19%
|
3.50
+48.53%
|
2.35
|
| Other Operating Expenses |
|
-0.79
-100.51%
|
-0.39
|
—
|
| Total Expenses |
|
71.56
+171.21%
|
26.38
+52.30%
|
17.32
|
| Operating Income |
|
-71.56
-171.21%
|
-26.38
-52.30%
|
-17.32
|
| Total Operating Income As Reported |
|
-72.35
-170.17%
|
-26.78
-54.57%
|
-17.32
|
| EBITDA |
|
-70.00
-170.22%
|
-25.90
-57.43%
|
-16.45
|
| Normalized EBITDA |
|
-70.00
-170.22%
|
-25.90
-57.43%
|
-16.45
|
| EBIT |
|
-70.00
-170.22%
|
-25.90
-57.43%
|
-16.45
|
| Net Income |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Pretax Income |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Net Non Operating Interest Income Expense |
|
1.56
+1601.92%
|
-0.10
-112.47%
|
0.83
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.58
+1525.00%
|
0.04
|
| Net Interest Income |
|
1.56
+1601.92%
|
-0.10
-112.47%
|
0.83
|
| Interest Expense |
|
0.00
-100.00%
|
0.58
+1525.00%
|
0.04
|
| Interest Income Non Operating |
|
1.56
+224.74%
|
0.48
-44.71%
|
0.87
|
| Interest Income |
|
1.56
+224.74%
|
0.48
-44.71%
|
0.87
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Net Income From Continuing Operation Net Minority Interest |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Net Income From Continuing And Discontinued Operation |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Net Income Continuous Operations |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Normalized Income |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Net Income Common Stockholders |
|
-83.37
-205.36%
|
-27.30
-65.57%
|
-16.49
|
| Diluted EPS |
|
-2.38
-73.30%
|
-1.37
+9.17%
|
-1.51
|
| Basic EPS |
|
-2.38
-73.30%
|
-1.37
+9.17%
|
-1.51
|
| Basic Average Shares |
|
35.08
+76.21%
|
19.91
+44.21%
|
13.80
|
| Diluted Average Shares |
|
35.08
+76.21%
|
19.91
+44.21%
|
13.80
|
| Diluted NI Availto Com Stockholders |
|
-83.37
-205.36%
|
-27.30
-65.57%
|
-16.49
|
| Preferred Stock Dividends |
|
13.38
+1541.47%
|
0.81
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
152.62
+174.82%
|
55.53
+216.22%
|
17.56
|
| Current Assets |
|
152.49
+174.59%
|
55.53
+216.22%
|
17.56
|
| Cash Cash Equivalents And Short Term Investments |
|
141.86
+167.24%
|
53.08
+225.75%
|
16.30
|
| Cash And Cash Equivalents |
|
21.77
-59.00%
|
53.08
+225.75%
|
16.30
|
| Other Short Term Investments |
|
120.10
|
0.00
|
—
|
| Receivables |
|
1.25
-8.73%
|
1.38
|
0.00
|
| Taxes Receivable |
|
1.25
-8.73%
|
1.38
|
0.00
|
| Prepaid Assets |
|
5.61
+440.37%
|
1.04
-14.92%
|
1.22
|
| Current Deferred Assets |
|
3.39
|
0.00
|
—
|
| Other Current Assets |
|
0.38
+902.63%
|
0.04
-17.39%
|
0.05
|
| Total Non Current Assets |
|
0.12
|
0.00
|
0.00
|
| Net PPE |
|
0.12
|
0.00
|
—
|
| Gross PPE |
|
0.12
|
0.00
|
—
|
| Other Properties |
|
0.12
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
273.63
+163.07%
|
104.02
+161.32%
|
39.80
|
| Current Liabilities |
|
9.15
+93.98%
|
4.72
+54.59%
|
3.05
|
| Payables And Accrued Expenses |
|
9.11
+92.98%
|
4.72
+54.59%
|
3.05
|
| Payables |
|
2.13
-5.43%
|
2.25
+21.38%
|
1.85
|
| Accounts Payable |
|
2.13
-5.43%
|
2.25
+21.38%
|
1.85
|
| Current Accrued Expenses |
|
6.98
+182.55%
|
2.47
+105.83%
|
1.20
|
| Other Current Liabilities |
|
0.05
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
264.48
+166.35%
|
99.30
+170.18%
|
36.75
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
|
0.00
-100.00%
|
0.79
|
| Long Term Debt |
|
—
|
—
|
0.79
|
| Long Term Capital Lease Obligation |
|
0.00
|
0.00
|
—
|
| Preferred Securities Outside Stock Equity |
|
264.48
+166.35%
|
99.30
+176.09%
|
35.97
|
| Stockholders Equity |
|
-121.01
-149.62%
|
-48.48
-117.97%
|
-22.24
|
| Common Stock Equity |
|
-121.01
-149.62%
|
-48.48
-117.97%
|
-22.24
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Share Issued |
|
35.08
+0.00%
|
35.08
+0.00%
|
35.08
|
| Ordinary Shares Number |
|
35.08
+0.00%
|
35.08
+0.00%
|
35.08
|
| Additional Paid In Capital |
|
2.35
+212.80%
|
0.75
+50.00%
|
0.50
|
| Retained Earnings |
|
-123.42
-150.70%
|
-49.23
-116.47%
|
-22.74
|
| Gains Losses Not Affecting Retained Earnings |
|
0.06
|
0.00
|
—
|
| Other Equity Adjustments |
|
0.06
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
-121.01
-149.62%
|
-48.48
-117.97%
|
-22.24
|
| Total Capitalization |
|
-121.01
-149.62%
|
-48.48
-125.95%
|
-21.46
|
| Working Capital |
|
143.34
+182.07%
|
50.82
+250.22%
|
14.51
|
| Invested Capital |
|
-121.01
-149.62%
|
-48.48
-125.95%
|
-21.46
|
| Total Debt |
|
0.00
|
0.00
-100.00%
|
0.79
|
| Capital Lease Obligations |
|
0.00
|
0.00
|
—
|
| Net Tangible Assets |
|
-121.01
-149.62%
|
-48.48
-117.97%
|
-22.24
|
| Tangible Book Value |
|
-121.01
-149.62%
|
-48.48
-117.97%
|
-22.24
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Operating Cash Flow |
|
-71.60
-202.27%
|
-23.69
-75.34%
|
-13.51
|
| Cash Flow From Continuing Operating Activities |
|
-71.60
-202.27%
|
-23.69
-75.34%
|
-13.51
|
| Net Income From Continuing Operations |
|
-70.00
-164.25%
|
-26.49
-60.63%
|
-16.49
|
| Other Non Cash Items |
|
0.84
-53.85%
|
1.82
-1.94%
|
1.85
|
| Stock Based Compensation |
|
1.44
+476.00%
|
0.25
+21.36%
|
0.21
|
| Change In Working Capital |
|
-3.89
-630.87%
|
0.73
-20.43%
|
0.92
|
| Change In Prepaid Assets |
|
-8.23
-594.94%
|
-1.19
-20.55%
|
-0.98
|
| Change In Payables And Accrued Expense |
|
4.39
+128.90%
|
1.92
+0.74%
|
1.90
|
| Change In Accrued Expense |
|
4.51
+254.84%
|
1.27
+131.51%
|
0.55
|
| Change In Payable |
|
-0.12
-118.89%
|
0.65
-52.29%
|
1.35
|
| Change In Account Payable |
|
-0.12
-118.89%
|
0.65
-52.29%
|
1.35
|
| Change In Other Current Liabilities |
|
-0.04
|
0.00
|
—
|
| Investing Cash Flow |
|
-118.86
|
0.00
|
—
|
| Cash Flow From Continuing Investing Activities |
|
-118.86
|
0.00
|
—
|
| Net PPE Purchase And Sale |
|
-0.02
|
0.00
|
—
|
| Purchase Of PPE |
|
-0.02
|
0.00
|
—
|
| Capital Expenditure |
|
-0.02
|
—
|
—
|
| Net Investment Purchase And Sale |
|
-118.83
|
0.00
|
—
|
| Purchase Of Investment |
|
-143.85
|
0.00
|
—
|
| Sale Of Investment |
|
25.02
|
0.00
|
—
|
| Financing Cash Flow |
|
159.14
+163.15%
|
60.48
+335.24%
|
13.89
|
| Cash Flow From Continuing Financing Activities |
|
159.14
+163.15%
|
60.48
+335.24%
|
13.89
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
7.66
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
8.51
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.84
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
8.51
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-0.84
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
7.66
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.16
|
0.00
|
—
|
| Net Other Financing Charges |
|
-0.45
-57.95%
|
-0.28
-708.57%
|
-0.04
|
| Changes In Cash |
|
-31.32
-185.13%
|
36.79
+9455.32%
|
0.39
|
| Beginning Cash Position |
|
53.08
+225.75%
|
16.30
+2.42%
|
15.91
|
| End Cash Position |
|
21.77
-59.00%
|
53.08
+225.75%
|
16.30
|
| Free Cash Flow |
|
-71.63
-202.37%
|
-23.69
-75.34%
|
-13.51
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.10
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
159.43
+200.27%
|
53.10
+281.17%
|
13.93
|
| Net Preferred Stock Issuance |
|
159.43
+200.27%
|
53.10
+281.17%
|
13.93
|
| Preferred Stock Issuance |
|
159.43
+200.27%
|
53.10
+281.17%
|
13.93
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|